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Small Failing Bioprosthesis?
An In Vitro Case StudyPrem A. Midha, MS,* Vrishank Raghav, PHD,* Jose F. Condado, MD, MS,y Sivakkumar Arjunon, PHD,*
Domingo E. Uceda, BS,* Stamatios Lerakis, MD,y Vinod H. Thourani, MD,y Vasilis Babaliaros, MD,y
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MaOBJECTIVES The aim of this study was to investigate the hemodynamic performance of a transcatheter heart valve
(THV) deployed at different valve-in-valve positions in an in vitro model using a small surgical bioprosthesis.
BACKGROUND Patients at high surgical risk with failing 19-mm surgical aortic bioprostheses are not candidates for
valve-in-valve transcatheter aortic valve replacement, because of risk for high transvalvular pressure gradients (TVPGs)
and patient-prosthesis mismatch.
METHODS A 19-mm stented aortic bioprosthesis was mounted into the aortic chamber of a pulse duplicator, and a
23-mm low-proﬁle balloon-expandable THV was deployed (valve-in-valve) in 4 positions: normal (bottom of the THV
stent aligned with the bottom of the surgical bioprosthesis sewing ring) and 3, 6, and 8 mm above the normal position.
Under controlled hemodynamic status, the effect of these THV positions on valve performance (mean TVPG, geometric
oriﬁce area, and effective oriﬁce area), thrombotic potential (sinus shear stress), and migration risk (pullout force and
embolization ﬂow rate) were assessed.
RESULTS Compared with normal implantation, a progressive reduction of mean TVPG was observed with each supra-
annular THV position (normal: 33.10 mm Hg; 3 mm: 24.69 mm Hg; 6 mm: 19.16 mm Hg; and 8 mm: 12.98 mm Hg;
p < 0.001). Simultaneously, we observed increases in geometric oriﬁce area (normal: 0.83 cm2; 8 mm: 1.60 cm2;
p < 0.001) and effective oriﬁce area (normal: 0.80 cm2; 8 mm: 1.28 cm2; p < 0.001) and reductions in sinus shear
stresses (normal: 153 dyne/cm2; 8 mm: 40 dyne/cm2; p < 0.001), pullout forces (normal: 1.55 N; 8 mm: 0.68 N;
p < 0.05), and embolization ﬂow rates (normal: 32.91 l/min; 8 mm: 26.06 l/min; p < 0.01).
CONCLUSIONS Supra-annular implantation of a THV in a small surgical bioprosthesis reduces mean TVPG but may
increase the risk for leaﬂet thrombosis and valve migration. A 3- to 6-mm supra-annular deployment could be an optimal
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AB BR E V I A T I O N S
AND ACRONYM S
EOA = effective oriﬁce area
GOA = geometric oriﬁce area
TAVR = transcatheter aortic
valve replacement
THV = transcatheter heart
valve
TVPG = transvalvular pressure
gradient
VIV = valve-in-valve
VSS = viscous shear stress
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2027V alve-in-valve (VIV) transcatheter aorticvalve replacement (TAVR) is a feasible treat-ment for patients with failing aortic bio-
prostheses (1). Although VIV implantation may
restore valve function and improve symptoms,
adverse events such as elevated post-procedural gra-
dients (28.4%), coronary obstruction (3.5%), device
malpositioning (15.0%), and valve leaﬂet thrombosis
(4%) have been reported (2–5). Current transcatheter
heart valves (THVs) were not designed for deploy-
ment into semirigid bioprostheses. Patients with
small surgical bioprostheses (i.e., 19- or 21-mm
valves) are generally excluded from VIV TAVR
because of the risk for patient-prosthesis mismatch.SEE PAGE 2034In these patients, some have experimented with
alternative techniques, such as supra-annular
deployment, in an attempt to bypass the geometric
constraints imposed by the bioprosthesis frame and
improve post-procedural gradients (6–8). However,
supra-annular deployment could increase the risk
for coronary obstruction (9), leaﬂet thrombosis from
ﬂow stagnation within the sinus region (10–14), and
THV migration (15). In this in vitro study, we attemp-
ted to bridge a gap in VIV TAVR knowledge by assess-
ing hemodynamic and potential safety parameters
using a low-proﬁle balloon-expandable THV at
different levels of implantation.
METHODS
FLOW LOOP. The study was conducted in the Georgia
Tech Left Heart Simulator (Figure 1), a validated pul-
satile ﬂow loop that simulates physiological and
pathophysiological conditions of the heart (16,17). TheFIGURE 1 In Vitro Pulsatile Flow System
The Georgia Tech Left Heart Simulator (left) used in this study is a valid
physiological conditions of the heart (16,17). Mean transvalvular pressure
aortic pressures as shown in the shaded region (right).surgical bioprosthesis was mounted in the
aortic chamber, which is an idealized rigid
acrylic chamber designed to simulate the
aortic sinus and ascending aorta (Figure 2).
The chamber dimensions were based on pub-
lished average anatomic measurements
(18,19). The ﬂow rate through the valve is
adjusted through a LabVIEW version 12 (Na-
tional Instruments Corporation, Austin,
Texas) triggered solenoid system that controls
a bladder pump and is measured through an
electromagnetic ﬂow probe (600 series, Car-
olina Medical Electronics, East Bend, North
Carolina). Aortic and ventricular pressure waveforms
(Figure 1) are tuned through lumped systemic resis-
tance and compliance and are measured with pressure
transducers (Deltran DPT-200, Utah Medical Products,
Inc., Midvale, Utah) on either side of the valve
annulus.
VALVE MODELS AND DEPLOYMENT. A 23-mm balloon-
expandable SAPIEN XT (Edwards Lifesciences,
Irvine, California) was deployed within a 19-mm
PERIMOUNT (17-mm inside diameter; Edwards Life-
sciences) in 4 positions: normal (bottom of the THV
stent aligned with the bottom of the surgical bio-
prosthesis sewing ring) and 3, 6, and 8 mm above the
normal position. Please note that the SAPIEN XT is
considered a low-proﬁle TAVR device. In all supra-
annular positions, a second balloon inﬂation was
performed to ﬂare the aortic end of THV (“ﬂower pot”
geometry; Figure 3).
HEMODYNAMIC VARIABLES. Mean transvalvular pres-
sure gradients (TVPG) were measured and used as
surrogates of VIV performance. The working ﬂuid was
a 3.5-cSt saline-glycerin solution (approximately 36%ated pulsatile ﬂow loop for producing physiological and patho-
gradient were determined by the difference between ventricular and
FIGURE 2 Aortic Chamber
The aortic chamber was designed on the basis of published
anatomic average values (18,19). The position shown is the 8-mm
valve-in-valve deployment. The dashed line indicates the region
of interest for the thrombosis studies.
FIGURE 3 Deploym
Schematic represent
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2028glycerin by volume in 0.9% NaCl) to match the kine-
matic viscosity of blood. The ﬂow rate was tuned for a
mean cardiac output of 5 l/min and a systolic duration
of 35%. The resistance and compliance were
then adjusted to ensure a diastolic aortic pressure of
80 mm Hg and a systolic pressure of 120 mm Hg
(Figure 1). Two hundred consecutive cardiac cycles
of hemodynamic data (aortic pressure, ventricular
pressure, and ﬂow rate) were collected for each
test condition at a 1-kHz data-sampling rate using a
custom LabVIEW Virtual Instrument.
AORTIC VALVE ORIFICE AREA. Geometric oriﬁce
area (GOA) was determined through en face high-
speed imaging using a Karl Storz 88630 SF bore-
scope (Karl Storz, Tuttlingen, Germany) connected
to a Basler A504k high-speed charge-coupled device
camera (Basler Corporation, Exton, Pennsylvania).
Four cardiac cycles (n ¼ 4) of data were collected forent Schematic
ation of deployment heights as they would be seen by x-ray.each implantation position. The images were manu-
ally segmented and scaled to determine peak systolic
GOA (Figure 4). Effective oriﬁce area (EOA) was
computed using the Gorlin equation (20):
EOA ¼ Q
51:6
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
TVPG
p : [Equation 1]
THROMBOSIS RISK. High-speed particle image
velocimetry experiments were conducted using the
ﬂow system described previously. The purpose of
these experiments was to obtain time-resolved mea-
surements of the ﬂow velocities in the sinus (Figure 2)
as a means of assessing relative risk for stagnation-
induced thrombosis. A diode-pumped solid-state
laser (2 W, 532 nm, Shenzhen optlaser Technologies,
Shenzhen, China) was used as the light source, a
custom LaVision scanner (LaVision, Göttingen, Ger-
many) was used to convert the continuous beam
into a high-frequency pulse, and a complementary
metal-oxide semiconductor camera (Phantom Miro
M/R/LC123, 1,920  1,200 pixels, 730 frames/s; Vision
Research, Wayne, New Jersey) was used to image the
particles in a single plane. Fluorescent polymeric
rhodamine-B particles of diameters 1 to 20 mm were
used as seeding particles to visualize the ﬂow ﬁeld
under laser illumination. The resultant velocity ﬁeld
in the sinus was used to calculate the viscous shear
stress (VSS) ﬁeld throughout the cardiac cycle and is
given by the following expression:
VSS ¼ m

vu
vy
þ vv
vx

: [Equation 2]
The VSS data presented in this work were
computed over 9 cardiac cycles. This velocity ﬁeld–
dependent measure is critically linked to thrombotic
potential of the leaﬂets of the valve (21,22).
PULLOUT FORCES. The pullout force was measured
as a means of determining the relative embolization
risk for each VIV implantation position. The bio-
prosthesis was sutured to the bottom of a rigid acrylic
chamber ﬁlled with saline using 2.0 Ethibond sutures
(Ethicon US, Somerville, New Jersey). A single con-
tinuous 2.0 Ethibond suture was also attached to the
THV stent at 3 equally spaced locations to ensure
equally distributed tension (Figure 5). The THV was
then deployed into the surgical bioprosthesis at the
desired location. The THV harness was attached to a
MARK-10 Series 3 digital force gauge (MARK-10,
Copiague, New York), which records at 10 Hz. Force
was applied gradually until the valve migrated and
the force measured by the gauge decreased. Because
of the “ﬂower pot” conﬁguration of the THV, the
FIGURE 4 En Face View Example
High-speed en face imaging of the valve-in-valve allows analytic
computation of the ﬂuid forces acting upon the transcatheter
heart valve.
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2029primary concern was antegrade migration into the
ascending aorta. Each test condition was repeated
4 times.
EMBOLIZATION FLOW RATE. In addition to pullout
forces, embolization risk was assessed by subjectingFIGURE 5 Pullout Force Chamber
The pullout force chamber is a rigid housing ﬁlled with saline in
which the surgical bioprosthesis is securely sutured. The trans-
catheter heart valve is deployed at the desired location and then
pulled by a uniaxial digital force gauge.each THV deployment to gradually increasing steady
antegrade ﬂow. The ﬂow rate at which each THV
deployment embolized was recorded. Each test was
repeated 4 times.
STATISTICAL ANALYSIS. The data are presented as
mean  SD. Normality of all data was tested using the
Anderson-Darling method. One-way analysis of vari-
ance was used to analyze independent sample sets
with Tukey’s post-hoc test for comparisons between
multiple groups. The pullout force data were not nor-
mally distributed, and therefore, a Mann-Whitney
U test was used instead. Values of p < 0.05 were
considered to indicate statistical signiﬁcance, and
the analysis was done using SPSS Statistics for Mac
version 20.0 (IBM Corporation, Armonk, New York).
RESULTS
HEMODYNAMIC VARIABLES. The TVPG is reported as
a mean measured over 299 cycles of gathered data
(Figure 6). The dashed red line indicates the threshold
for device success as deﬁned by Valve Academic
Research Consortium-2 (23) and American Heart As-
sociation and American College of Cardiology (24)
guidelines. As expected, our normal VIV position
resulted in a signiﬁcantly higher mean TVPG than the
surgical bioprosthesis alone (33.10  0.37 mm Hg vs.
13.07  0.16 mm Hg; p < 0.001). These TVPGs pro-
gressively decreased with each supra-annular im-
plantation to 24.69  0.38 mm Hg, 19.16  0.26
mm Hg, and 12.98  0.25 mm Hg at supra-annular 3, 6,
and 8 mm, respectively. At 8 mm above normalFIGURE 6 Mean Transvalvular Pressure Gradients
Increasingly supra-annular transcatheter heart valve deployment
yields increasingly more favorable mean transvalvular pressure
gradients (TVPGs). The dashed red line indicates the threshold
for mild aortic stenosis. The error bars indicate SD, and all
p values are <0.001.
FIGURE 7 Aortic Valve Area
Supra-annular transcatheter heart valve deployment resulted in
increased geometric oriﬁce area and effective oriﬁce area. The
dashed line indicates the threshold for severe aortic valve
stenosis (24). The error bars indicate SD, and all p values are
<0.001.
FIGURE 8 Sinus Flow (Viscous Shear Stress)
The maximal viscous shear stress (VSS) over the cardiac cycle
decreases with increasingly supra-annular transcatheter heart
valve deployment. The error bars indicate SD, and all p values
are <0.01.
FIGURE 9 Pullout Forces
The magnitude of force required to dislodge the transcatheter
heart valve (THV) in valve-in-valve (VIV) is plotted as the pullout
force measured by a digital force gauge. The dashed red line
indicates the analytically derived ﬂuid forces experienced by a
THV in VIV. The solid red line indicates the ﬂuid forces on the
same deployment if it were to undergo 10% more stenosis by
area. The error bars indicate SD, and all p values are <0.05.
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2030implantation, the mean TVPG was similar to the
control case and was the lowest TVPG for any VIV
position.
The reduction in mean TVPG with increasingly
supra-annular VIV deployment was due primarily to
increases in GOA (Figure 7) through further ﬂaring of
the THV (more exaggerated “ﬂower pot” geometry).
The dashed line in the ﬁgure indicates the threshold
for severe aortic valve stenosis (24). The GOA of the
control case was 1.78  0.01 cm2 and dropped to 0.83
 0.01 cm2 after deployment in the normal position
(p < 0.001). At successively supra-annular positions,
the GOA increased from 0.99  0.01 cm2 to 1.2  0.01
cm2 and to 1.6  0.02 cm2 (p < 0.001).
THROMBOSIS RISK. The VSS results are maximum
values obtained after spatial integration of the shear
stress ﬁelds over the area of the sinus at each time
point in the cardiac cycle. Figure 8 illustrates the
variation of maximum VSS among THV deployments.
It was observed that the VSS decreases with in-
creasing deployment height of the THV, ranging from
1.53  0.21 to 0.40  0.10 dyne/cm2 (p < 0.01). Given
that human blood has been shown to form aggregates
at shear rates <46 s1 (1.61 dyne/cm2), the stagnation-
induced thrombosis safety threshold lies above all
VIV deployments (14).
PULLOUT FORCES. The pullout forces are reported as
mean  SD. With each successive supra-annular
deployment, the contact area between the THV and
surgical aortic valve replacement reduced, resulting
in lower required force for migration. Although the
THV did not migrate under physiological pulsatile
ﬂow conditions at any of the deployment positions,the measured pullout force reduced drastically be-
tween normal and 3-mm supra-annular deployment
positions (1.55 vs. 0.9125 N, p ¼ 0.029) and steadily
reduced across the 3- to 8-mm positions, as shown in
Figure 9 (p < 0.06).
In this study, migration into the left ventricle
was not a concern, because the supra-annular im-
plantation provides additional “geometric” resistance
under retrograde ﬂow. Dwyer et al. (25) derived esti-
mates of ﬂuid forces on a transcatheter valve on the
basis of pressure gradients, viscous forces, and
FIGURE 10 Embolization Flow Rates
Each valve-in-valve deployment was subjected to gradually
increasing steady ﬂow until the transcatheter heart valve
embolized. The error bars indicate SD, and all indicated p values
are <0.05.
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2031momentum changes and showed that pressure forces
accounted for approximately 75% of the total forces.
On the basis of these results, a baseline safety
threshold was computed (Figure 9):
Total fluid force ¼ TVPG A
0:75
[Equation 3]
A ¼ GOASAVR  GOATAVR [Equation 4]
where GOASAVR is the maximum surgical bio-
prosthesis GOA on the basis of the internal diameter
of the valve, and GOATAVR is the GOA determined
using en face imaging of the deployed THV (Figure 4).
This threshold represents the theoretical lower limit
of pullout force necessary to avoid embolization.
Applying a theoretical additional 10% stenosis by area
to this threshold yields the upper safety threshold
shown in Figure 9. It should be noted that the 3-mm
implantation position does not meet this upper
safety threshold.
EMBOLIZATION FLOW RATE. The embolization ﬂow
rates followed a similar trend as the pullout forces,TABLE 1 Compiled Results
Variable Sample Size (n) Safety Threshold Cont
Mean TVPG (mm Hg) 200 20 13.07 
GOA (cm2) 4 1 1.78 
EOA (cm2) 200 1 1.28 
Maximal VSS (dyne/cm2) 9 1.61 2.05 
Pullout force (N) 4 See Figure 9 —
Embolization ﬂow rate (l/min) 4 30 —
The compiled results are represented as mean  SD compared with a threshold value. R
EOA ¼ effective oriﬁce area; GOA ¼ geometric oriﬁce area; TVPG ¼ transvalvular prethough the separation between deployments was not
as distinct (Figure 10). The normal deployment
embolized at 32.91  0.85 l/min, while the supra-
annular deployments of 3, 6, and 8 mm embolized
at 31.57  0.75 l/min, 29.37  0.73 l/min, and 26.06 
1.27 l/min, respectively. The safety threshold of 30
l/min was deﬁned by a peak instantaneous systolic
ﬂow rate through the aortic valve in a healthy adult
with a cardiac output of 5 to 6 l/min (26). Most TAVR
patients have some degree of impaired cardiac
output, making 30 l/min peak instantaneous ﬂow
rate a fairly conservative threshold.
DISCUSSION
The results of this study (Table 1) suggest that supra-
annular THV implantation can lead to lower mean
TVPG than “normal” implantation after VIV TAVR in
patients with small surgical bioprostheses (w19 mm).
We found that increasingly supra-annular deployment
resulted in even lower TVPGs, ultimately reaching
similar values to our control (a normal functioning
bioprosthetic valve). This improvement of gradients
can be explained by a better expansion of the down-
stream portion of the THV at supra-annular locations,
demonstrated by the larger GOA measurements
and EOA calculations at these levels. Thus, high-
implantation VIV TAVR could be performed with good
outcomes in patients at high surgical risk who, to this
date, are not considered candidates because of the
sizesof their original surgical bioprostheses.Moreover,
prior clinical registries have reported that VIV TAVR
in patients with small surgical bioprostheses (deﬁned
as #21 mm) have higher mortality than patients with
larger surgical bioprostheses who undergo this same
procedure, mostly because the former are associated
with an increased rate of patient-prosthesis mismatch
and elevated TVPGs (27). Although we focused only
on the hemodynamic data of high-implantation VIV
TAVR in a 19-mm surgical bioprosthesis, we propose
that such a procedure may beneﬁt patients with
surgical bioprostheses of other sizes.rol Normal þ3 mm þ6 mm þ8 mm
0.16 33.10  0.37 24.69  0.38 19.16  0.26 12.98  0.25
0.01 0.83  0.01 0.99  0.01 1.20  0.01 1.60  0.02
0.01 0.80  <0.01 0.93  <0.01 1.06  <0.01 1.28  0.01
0.35 1.53  0.21 1.31  0.28 0.63  0.16 0.40  0.10
1.55  0.20 0.91  0.07 0.76  0.06 0.68  0.02
32.91  0.85 31.57  0.75 29.37  0.73 26.06  1.27
esults in italics did not meet the threshold criterion.
ssure gradient; VSS ¼ viscous shear stress.
PERSPECTIVES
WHAT IS KNOWN? Patients with small surgical
bioprostheses are generally excluded from VIV TAVR
because of the risk for patient-prosthesis mismatch.
We performed a risk-beneﬁt analysis of supra-annular
deployment of a THV in one such simulated in vitro
patient.
WHAT IS NEW? On the basis of the evidence from
this work, we recommend VIV deployment of a THV
between 3 and 6 mm supra-annular in a patient with a
small failing bioprosthesis. However, clinicians are
strongly urged to consider patient-speciﬁc anatomic
characteristics and carefully weigh the beneﬁt of high
THV implantation in reducing post-procedural gradi-
ents against the potential risk for valve leaﬂet
thrombosis and device migration in potential candi-
dates for VIV TAVR.
WHAT IS NEXT? Similar in vitro studies using other
surgical bioprostheses and TAVR devices, including
the Medtronic CoreValve, are critically important to
optimize VIV performance and patient outcomes.
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2032The observed beneﬁt of high THV implantation
measured by mean TVPG could be eclipsed by an
increased risk for leaﬂet thrombosis. Increasingly
supra-annular deployment resulted in reduced sinus
velocities and VSS levels, which could increase the risk
for leaﬂet thrombosis from ﬂow stagnation (13,14).
Recent evidence suggests that thrombosis is an
underreported problem affecting THVs. However, the
pathophysiology of this process is poorly understood,
with most thrombus deposition occurring on the valve
leaﬂets (5,28–30). Although none of our VIV TAVR
deployment positions yielded VSS levels higher than
the currently understood safety threshold values for
thrombus formation, the exact clinical signiﬁcance of
this ﬂow stagnation remains unclear and needs further
investigation. Traditionally, thrombosis is discussed
in terms of Virchow’s triad (materials, biochemistry,
and ﬂuid ﬂow), and the conditions that inﬂuence
thrombosis risk are highly patient speciﬁc. Our
in vitro model did not incorporate factors such as
aortic distensibility and coronary ﬂow and does not
account for patient-speciﬁc anatomy or physiology,
which can alter thrombosis risk. Because the
intention of our study was to understand the ﬂuid
mechanics and hemodynamic implications of an
alternative deployment, we focused on inspecting
the differences observed in thrombosis risk strictly
on the basis of ﬂuid mechanics metrics.
We also observed that supra-annular THV implan-
tation resulted in a reduction of force necessary to
dislodge the THV. Interestingly, we found that the
largest drop in pullout force occurred between the
normal and the 3-mm deployments, possibly because
of a reduction of the contact area with the internal
surface of the surgical bioprosthesis suture cuff. The
coefﬁcient of friction between the THV stent and the
surgical bioprosthesis suture cuff is likely substantially
higher than between the THV stent and the surgical
bioprosthesis leaﬂets. Therefore, there is a gradual
decrease in the pullout force at further supra-annular
positions, where the contact area of the THV stent
with the suture cuff is minimal. Although these
lower forces could translate to an increased risk for
valve migration, especially in situations of high
cardiac output, the calculated (and conservative)
baseline safety threshold for valve migration was
never reached under physiologic pulsatile ﬂow
conditions, even at the highest THV implantation
(8 mm). Furthermore, the commonly seen calciﬁ-
cation and ﬁbrosis in failing bioprostheses is likely
to increase the amount of force required to dislodge
the THV in a patient, suggesting that in a worst-
case scenario, though possible, antegrade THV
embolization is unlikely to occur.CONCLUSIONS
On the basis of this in vitro evidence and threshold
values, we recommend deployment of a SAPIEN XT
valve between 3 and 6 mm supra-annular in a patient
with a failing 19-mm PERIMOUNT. Although we
acknowledge the limitations of this study, we would
like to emphasize that clinicians must consider
patient-speciﬁc anatomic characteristics and care-
fully weigh the beneﬁt of high THV implantation in
reducing post-procedural gradients against the po-
tential risk for valve leaﬂet thrombosis and device
migration in potential candidates for VIV TAVR.
Similar in vitro studies using other surgical bio-
prostheses and TAVR devices, including the Med-
tronic CoreValve, are critically important to optimize
VIV performance and patient outcomes.
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